Veracyte Inc
Research Veracyte Inc (VCYT) on Bullrun: valuation model: 24.9% overvalued, market cap USD 4.80B, P/E 55.4. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVCYT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Valuation signal24.9% overvalued
- Market capUSD 4.80B
- P/E55.4
- Financial periodFY2025
- RevenueUSD 517.15M
- Revenue growth16.0%
- Net incomeUSD 66.40M
- Free cash flowUSD 126.63M
- Gross margin70.1%
Valuation Snapshot
Bullrun's latest valuation model marks Veracyte Inc as 24.9% overvalued; latest market cap is USD 4.80B; P/E is 55.4.
About Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services.
Frequently asked questions
Is Veracyte Inc overvalued or undervalued?
Bullrun's valuation model currently marks Veracyte Inc as 24.9% overvalued.
What is Veracyte Inc's market cap?
Veracyte Inc's market capitalization is USD 4.80B.
What is Veracyte Inc's P/E ratio?
Veracyte Inc's price-to-earnings (P/E) ratio is 55.4.
What does Veracyte Inc do?
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis;